AUG 31, 2021 7:00 AM PDT

Convalescent Plasma Therapy for COVID-19 Doesn't Work

WRITTEN BY: Tara Fernandez

After encountering an infectious agent, the immune system begins churning out antibodies—Y-shaped warriors that neutralize pathogens—into the blood circulation. In theory, donor blood from patients who have recovered from an infection could be used therapeutically, helping those experiencing severe symptoms recover.

In the case of COVID-19, the U.S. Food and Drug Administration (FDA) granted emergency authorization for convalescent plasma therapy earlier on in the pandemic. This therapy was targeted towards patients in hospitals suffering from COVID-19, particularly those who were immunocompromised. Since its authorization, tens of thousands of patients in the U.S. have been administered convalescent plasma therapy, despite the lack of clinical trial data to support the efficacy of the treatment.

Now, a recent study by Stanford researchers has revealed the harsh reality of convalescent plasma therapy for COVID-19: it doesn’t work.

A clinical trial called C3P0 was initiated by researchers at the National Institutes of Health around a year ago. The study aimed to understand how high-risk patients (such as those with underlying medical conditions such as asthma and Type 2 diabetes) would benefit from convalescent plasma therapy at the early stages of COVID-19 infection. This subset of patients is especially prone to progressing on to more severe, life-threatening symptoms of the disease, and early on during the pandemic, there were very few clinical options to support their recovery.

In February—despite only enrolling around 500 of the targeted 900 study participants—the C3PO study was terminated after researchers found no benefit of convalescent plasma at resisting severe COVID-19 symptoms compared to the placebo. 

Initially, researchers involved in the study estimated that plasma therapy might slash the risk of COVID-19 progression by around 10 percent. However, the clinical data collected from C3PO revealed that this number was under two percent.

“While this trial was negative, we need to continue this research to understand when passive immunotherapy such as convalescent plasma can be effective in treating emerging infectious diseases,” commented Kevin Schulman, one of the lead investigators involved in this work.

 

Source: The New England Journal of Medicine, Stanford Medicine.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 03, 2021
Immunology
Some Neutralizing Antibodies Make COVID Worse
AUG 03, 2021
Some Neutralizing Antibodies Make COVID Worse
Antibodies are specialized proteins produced as part of the body's immune response. Neutralizing antibodies bind to ...
AUG 19, 2021
Cancer
Japanese Berry Vine Could Treat Lung Cancer
AUG 19, 2021
Japanese Berry Vine Could Treat Lung Cancer
A berry-producing vine in Japan has shown promise in mouse models for treating lung cancer. The corresponding study was ...
AUG 18, 2021
Neuroscience
Histamine Regulates Serotonin Levels in Depression
AUG 18, 2021
Histamine Regulates Serotonin Levels in Depression
Heightened histamine levels from inflammation inhibit the effects of the mood-regulating neurotransmitter serotonin in t ...
OCT 07, 2021
Immunology
A 3D-Printed COVID Vaccine Patch?
OCT 07, 2021
A 3D-Printed COVID Vaccine Patch?
Even the bravest souls can get a little nervous when it comes to rolling up their sleeves and getting a shot. Aichmophob ...
OCT 19, 2021
Immunology
Reverse Vaccinations Tame the Immune System to Help Hemophilia Patients
OCT 19, 2021
Reverse Vaccinations Tame the Immune System to Help Hemophilia Patients
In patients with hemophilia A—a hereditary disorder where the blood cannot clot properly—their immune system ...
OCT 18, 2021
Genetics & Genomics
A Decade After Gene Therapy, SCID Patients Are Doing Well
OCT 18, 2021
A Decade After Gene Therapy, SCID Patients Are Doing Well
For decades, scientists have been trying to find ways to cure disorders that can be traced back to an error in one gene. ...
Loading Comments...